https://www.selleckchem.com/products/hs148.html
This prospective, pharmacodynamic study aimed to explore the potential applicability of a low-dose ticagrelor regimen in a heterogeneous Trinidadian subpopulation. Patients with stable coronary artery disease (n = 25) who were actively treated with dual antiplatelet therapy of aspirin 81mg daily and clopidogrel 75mg daily were recruited. Platelet function was measured with the VerifyNow P2Y assay (Accriva Diagnostics, San Diego, CA, USA) and assessed before initiation of and after 14days of treatment with a low-dose ticagrelor 45mg twice
Like
Comment
Share
